Advertisement

Advertisement

DE:PBDA Stock Latest News

Netflix downgraded, SanDisk initiated: Wall Street’s top analyst calls

The FlyNetflix downgraded, SanDisk initiated: Wall Street’s top analyst calls

Protalix Biotherapeutics Earnings Call Signals Strong Momentum

PremiumCompany Announcements

Protalix Biotherapeutics Earnings Call Signals Strong Momentum

1M ago

PLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

PLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

Protalix Shareholders Approve Directors, Compensation and Incentive Plan

PremiumCompany Announcements

Protalix Shareholders Approve Directors, Compensation and Incentive Plan

3M ago

Ram Selvaraju Reiterates Buy on Protalix, Maintains $12 Price Target on Elfabrio Momentum and Pipeline Upside

PremiumRatings

Ram Selvaraju Reiterates Buy on Protalix, Maintains $12 Price Target on Elfabrio Momentum and Pipeline Upside

4M ago

Protalix Highlights Elfabrio Dosing Approvals and Growth Plans

PremiumCompany AnnouncementsProtalix Highlights Elfabrio Dosing Approvals and Growth Plans

4M ago

Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets

Company Announcements

Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets

5M ago

PLX Upcoming Earnings Report: What to Expect?

Pre-Earnings

PLX Upcoming Earnings Report: What to Expect?

5M ago

Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs

PremiumCompany Announcements

Protalix Earnings Call: EU Win, Cash Boost, Trade-Offs

6M ago

Protalix: EU Approval and Commercial Tailwinds for Elfabrio Underscore Undervalued Upside

PremiumRatings

Protalix: EU Approval and Commercial Tailwinds for Elfabrio Underscore Undervalued Upside

7M ago

PLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

PLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

7M ago

Protalix Gains EU Approval for Extended Elfabrio Dosing

PremiumCompany Announcements

Protalix Gains EU Approval for Extended Elfabrio Dosing

7M ago

Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

PremiumThe FlyProtalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

7M ago

Protalix Highlights Positive EMA Opinion on Elfabrio Dosing

Company Announcements

Protalix Highlights Positive EMA Opinion on Elfabrio Dosing

8M ago

Protalix Wins EMA Panel Backing for New Elfabrio Dosing

Company Announcements

Protalix Wins EMA Panel Backing for New Elfabrio Dosing

8M ago

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

PremiumThe Fly

Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing

8M ago

Protalix outlines 2026 rare-disease growth and pipeline strategy

PremiumCompany Announcements

Protalix outlines 2026 rare-disease growth and pipeline strategy

9M ago

Protalix: Pipeline Expansion and Elfabrio Growth Drive Attractive Risk‑Reward and Undervalued Buy Rating

PremiumRatings

Protalix: Pipeline Expansion and Elfabrio Growth Drive Attractive Risk‑Reward and Undervalued Buy Rating

10M ago

Protalix, Secarna Pharmaceuticals enter collaboration and option agreement

PremiumThe Fly

Protalix, Secarna Pharmaceuticals enter collaboration and option agreement

10M ago

Protalix price target lowered to $12 from $15 at H.C. Wainwright

PremiumThe FlyProtalix price target lowered to $12 from $15 at H.C. Wainwright

10M ago

Protalix BioTherapeutics Reports Strong Revenue Growth in 2025

Company Announcements

Protalix BioTherapeutics Reports Strong Revenue Growth in 2025

11M ago

Protalix BioTherapeutics’ Earnings Call Highlights Growth and Challenges

Company Announcements

Protalix BioTherapeutics’ Earnings Call Highlights Growth and Challenges

11M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >